Transcriptomic Analysis Reveals JAK2/MPL-Independent Effects of Calreticulin Mutations in a C. elegans Model
Authors:
Open Access
Abstract
There is growing evidence that Ph-negative myeloproliferative neoplasms (MPNs) are disorders in which multiple molecular mechanisms are significantly disturbed. Since their discovery, CALR driver mutations have been demonstrated to trigger pathogenic mechanisms apart from the well-documented activation of JAK2/MPL-related pathways, but the lack of experimental models harboring CALR mutations in a JAK2/MPL knockout background has hindered the research on these non-canonical mechanisms. In this study, CRISPR/Cas9 was performed to introduce homozygous patient-like calreticulin mutations in a C. elegans model that naturally lacks JAK2 and MPL orthologs. Whole-genome transcriptomic analysis of these worms was conducted, and some of the genes identified to be associated with processes involved in the pathogenesis of MPNs were further validated by qPCR. Some of the transcriptomic alterations corresponded to typically altered genes and processes in cancer and Ph-negative MPN patients that are known to be triggered by mutant calreticulin without the intervention of JAK2/MPL. However, interestingly, we have also found altered other processes described in these diseases that had not been directly attributed to calreticulin mutations without the intervention of JAK2 or MPL. Thus, these results point to a new experimental model for the study of the JAK2/MPL-independent mechanisms of mutant calreticulin that induce these biological alterations, which could be useful to study unknown non-canonical effects of the mutant protein. The comparison with a calreticulin null strain revealed that the alteration of all of these processes seems to be a consequence of a loss of function of mutant calreticulin in the worm, except for the dysregulation of Hedgehog signaling and flh-3. Further analysis of this model could help to delineate these mechanisms, and the verification of these results in mammalian models may unravel new potential therapeutic targets in MPNs. As far as we know, this is the first time that a C. elegans strain with patient-like mutations is proposed as a potential model for leukemia research.Keywords
Funding Information
- University of Navarra (15058203)
This publication has 41 references indexed in Scilit:
- MicroRNA-Regulated Pathways in Hematological Malignancies: How to Avoid Cells Playing Out of TuneInternational Journal of Molecular Sciences, 2013
- Calreticulin signaling in health and diseaseThe International Journal of Biochemistry & Cell Biology, 2012
- Constitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative DisorderPLOS ONE, 2011
- The FLYWCH transcription factors FLH-1, FLH-2, and FLH-3 repress embryonic expression of microRNA genes in C. elegansGenes & Development, 2008
- Role of Peroxisome Proliferator‐Activated Receptor Gamma and Its Ligands in the Treatment of Hematological MalignanciesPPAR Research, 2008
- Differential Requirement of Unfolded Protein Response Pathway for Calreticulin Expression in Caenorhabditis elegansJournal of Molecular Biology, 2007
- Myeloproliferative disorders: the centrosome connectionLeukemia, 2005
- Calreticulin, a Calcium-binding Molecular Chaperone, Is Required for Stress Response and Fertility inCaenorhabditis elegansMolecular Biology of the Cell, 2001
- AC.elegans gene encodes a protein homologous to mammalian calreticulinDNA Sequence, 1992
- Platelet membrane fatty acids in thrombocytosis due to myeloproliferative disordersCell Biochemistry and Function, 1984